Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. (ADVM) generated a stream of news as a clinical-stage gene therapy company focused on highly prevalent ocular diseases, particularly neovascular or wet age-related macular degeneration (wet AMD). Company releases consistently describe Adverum’s goal of establishing intravitreal gene therapy as a new standard of care, using durable, single-administration treatments to preserve sight and potentially prevent blindness.
News coverage for ADVM has centered on the development of its lead gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly ADVM-022). Updates have included milestones in the pivotal Phase 3 ARTEMIS trial for wet AMD, such as initiation, screening progress, and the completion of target enrollment of 284 patients, as reported in SEC filings and press releases. Additional articles have highlighted long-term follow-up data from earlier studies like OPTIC and LUNA, as well as scientific presentations on Ixo-vec biodistribution and aflibercept expression in the eye.
Investors following ADVM-related news can also see announcements about regulatory designations for Ixo-vec, including Fast Track and RMAT status from the U.S. FDA, PRIME designation from the European Medicines Agency, and the Innovation Passport in the UK. Corporate updates have covered financing activities, inducement equity grants under the 2017 Inducement Plan, and participation in ophthalmology conferences.
A major theme in later news is the strategic transaction with Eli Lilly and Company. Releases dated October and December 2025 detail Lilly’s tender offer to acquire all outstanding Adverum shares for cash plus a non-tradable contingent value right (CVR), and the subsequent expiration and completion of the tender offer with all conditions satisfied. This news page therefore serves both as a record of Adverum’s clinical and corporate developments and as an archive of announcements leading up to and including its acquisition by Lilly.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) has granted 130,000 stock options to a new employee as an inducement for joining the company. This grant was made on May 9, 2022, in accordance with Nasdaq Rule 5635(c)(4). The options have an exercise price equal to the stock's closing price on the grant date and will vest over four years, contingent on the employee's continued service. Adverum focuses on gene therapies for ocular and rare diseases, including its candidate ADVM-022 for wet age-related macular degeneration.
Adverum Biotechnologies (Nasdaq: ADVM) announced the presentation of new data at the ASGCT 2022 Annual Meeting from May 16-19, 2022. Key highlights include findings from the OPTIC study evaluating the impact of neutralizing antibodies on ADVM-022's efficacy in treating wet age-related macular degeneration (AMD). Adverum plans to initiate a Phase 2 trial in Q3 2022, testing a higher and a lower dose of ADVM-022. Additionally, the company will present data on ADVM-062, aimed at blue cone monochromacy, which received Orphan Drug Designation from the FDA in January 2022.
Adverum Biotechnologies (Nasdaq: ADVM) presented new findings from the OPTIC study of ADVM-022 for wet age-related macular degeneration (AMD) at the ARVO 2022 meeting. The analysis demonstrated an 81% reduction in mean annualized anti-VEGF injections for all patients and up to 94% for those with baseline neutralizing antibodies (NAbs) 1:125. No safety concerns were linked to NAbs levels. Moving forward, Adverum plans to initiate a Phase 2 clinical trial with the first patient expected to be dosed in Q3 2022.
Adverum Biotechnologies announced that Szilárd Kiss, M.D. will present new analyses from the Phase 1 OPTIC Trial of ADVM-022 in wET AMD at the ARVO 2022 Annual Meeting on May 1, 2022. The trial showed over 80% reduction in annual anti-VEGF injections with the 2E11 dose. New data indicate a correlation between neutralizing antibodies (NAbs) and treatment efficacy. ADVM-022 was well tolerated, with no need for steroids post-treatment. Additionally, on April 18, 2022, Adverum granted stock options to an employee as part of an inducement grant.
Adverum Biotechnologies (Nasdaq: ADVM) has announced plans to complete the Investigational New Drug (IND) amendment process by mid-2022, allowing them to initiate the Phase 2 trial of ADVM-022 for wet age-related macular degeneration (wet AMD) in the third quarter of 2022. Following feedback from the FDA, the trial will evaluate two dosage levels of ADVM-022, aiming for a single intravitreal injection as a durable treatment option. The planned trial responds to the urgent need for long-lasting treatments for wet AMD patients.
Adverum Biotechnologies (Nasdaq: ADVM) reported its Q4 and full-year 2021 financial results, highlighting a net loss of $34.4 million, or $0.35 per share, compared to $37.6 million, or $0.39 per share in Q4 2020. The company plans to initiate a Phase 2 trial for ADVM-022 in wet age-related macular degeneration (AMD) in Q3 2022, bolstered by positive Phase 1 OPTIC trial results showing over 80% reduction in anti-VEGF injections. Cash reserves were $305.2 million at year-end, sufficient to fund operations into 2024.
Adverum Biotechnologies (Nasdaq: ADVM) has appointed Dr. Rabia Gurses Ozden and Ms. Soo J. Hong as independent members of its Board of Directors. Dr. Ozden brings 20 years of experience in ophthalmology and gene therapy, while Ms. Hong specializes in human capital management and executive development. Their expertise is expected to support the advancement of ADVM-022, a gene therapy candidate for treating wet age-related macular degeneration, toward a Phase 2 trial. The company aims to enhance its clinical development and talent retention strategies.
Adverum Biotechnologies (Nasdaq: ADVM) announced that its CEO, Laurent Fischer, M.D., will participate in a panel discussion at the 42nd Annual Cowen Healthcare Conference on March 7, 2022, at 2:10 p.m. ET. The discussion will focus on auditory and ophthalmology topics, highlighting Adverum's commitment to addressing unmet medical needs in ocular and rare diseases. The event will be accessible via a live webcast, with a replay available for 30 days post-event. The conference runs from March 7-9, 2022, showcasing various healthcare industry insights.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced the appointment of Dr. Richard Beckman as Chief Medical Officer, effective February 7, 2022. Dr. Beckman, a board-certified ophthalmologist with 30 years of experience in ophthalmology and drug development, will lead the company's global clinical development and medical affairs. He aims to advance the clinical program, ADVM-022, for treating wet age-related macular degeneration. Additionally, he received a stock option to purchase 485,000 shares as part of his inducement grant.
Adverum Biotechnologies (Nasdaq: ADVM) announced the appointment of Star Seyedkazemi, Pharm.D., as its Chief Development Officer. Dr. Seyedkazemi joins the executive committee and will focus on advancing the lead clinical program, ADVM-022, aimed at treating wet age-related macular degeneration (wet AMD). She brings over 16 years of experience in clinical development from companies like Allergan and Pliant Therapeutics. An inducement grant of stock options for 425,000 shares was also provided, vesting over four years. This leadership change aims to strengthen Adverum’s clinical operations.